Inflammatory bowel disease in pregnancy
- PMID: 28483847
- PMCID: PMC5422151
- DOI: 10.1503/cmaj.160967
Inflammatory bowel disease in pregnancy
Conflict of interest statement
Competing interests: The authors are involved in a research project supported by the MSI Foundation and the American College of Gastroenterology regarding improving clinical pathways in IBD care during pregnancy. Cynthia Seow has received honoraria as an advisory board member for Janssen Pharmaceutical, AbbVie, Shire, Actavis, Takeda Canada and Ferring Pharmaceuticals; speaker fees from Janssen Pharmaceutical and AbbVie; and research and educational support from Janssen Pharmaceutical and AbbVie. No other competing interests were declared.
References
-
- The impact of inflammatory bowel disease in Canada: 2012 final report and recommendations. Toronto: Crohn’s and Colitis Foundation of Canada; 2012. Available: www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf (accessed 2016 Nov. 1).
-
- O’Toole A, Nwanne O, Tomlinson T. Inflammatory bowel disease increases risk of adverse pregnancy outcomes: a meta-analysis. Dig Dis Sci 2015;60:2750–61. - PubMed
-
- de Lima A, Zelinkova Z, Mulders AG, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clin Gastroenterol Hepatol 2016;14:1285–92.e1. - PubMed
-
- Nguyen GC, Seow CH, Maxwell C, et al. IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150:734–57.e1. - PubMed
-
- Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology 2016;151: 110–9. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical